Structural and Functional Characterization of the Aryl Hydrocarbon Receptor Ligand Binding Domain by Homology Modeling and Mutational Analysis
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 10 of the 32 sources its claims cite were checked for support.
Abstract
The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that is activated by a structurally diverse array of synthetic and natural chemicals, including toxic halogenated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Analysis of the molecular events occurring in the AhR ligand binding and activation processes requires structural information on the AhR Per-Arnt-Sim (PAS) B-containing ligand binding domain, for which no experimentally determined structure has been reported. With the availability of extensive structural information on homologous PAS-containing proteins, a reliable model of the mouse AhR PAS B domain was developed by comparative modeling techniques. The PAS domain structures of the functionally related hypoxia-inducible factor 2alpha (HIF-2alpha) and AhR nuclear translocator (ARNT) proteins, which exhibit the highest degree of sequence identity and similarity with AhR, were chosen to develop a two-template model. To confirm the features of the modeled domain, the effects of point mutations in selected residue positions on both TCDD binding to the AhR and TCDD-dependent transformation and DNA binding were analyzed. Mutagenesis and functional analysis results are consistent with the proposed model and confirm that the cavity modeled in the interior of the domain is indeed involved in ligand binding. Moreover, the physicochemical characteristics of some residues and of their mutants, along with the effects of mutagenesis on TCDD and DNA binding, also suggest some key features that are required for ligand binding and activation of mAhR at a molecular level, thus providing a framework for further studies.
Overview
CoChat Summary
## TL;DR
The paper builds and validates a homology model of the mouse AhR PAS B ligand-binding domain using HIF-2α and ARNT as templates, because no experimental AhR structure was available. Site-directed mutagenesis and binding assays support a buried cavity as the TCDD-binding site and identify residues that affect ligand binding and/or ligand-dependent DNA binding.
## Key findings
- The best-supported model was the two-template HIF-2α/ARNT model: its PROSA z-score was -4.53 on average (best model -4.56), compared with -4.00 for the HIF-2α-only model; the multitemplate model was judged slightly better than the single-template one.
- CASTp identified a buried cavity in the modeled AhR domain with a volume of 496 ų, and comparison of modeled and template structures suggested this cavity could accommodate ligand binding.
- Mutagenesis showed that residues pointing outside the cavity generally did not affect TCDD binding, while cavity-facing or connector residues often did: H285A, I332P, M334E, and A375L completely eliminated both [³H]TCDD binding and TCDD-inducible DNA binding; C327A, M334A, E339A, A375V, and Q377A reduced DNA binding.
- Quantitatively, Table 4 reports that TCDD-inducible DNA binding was 100% for wild-type AhR, 97% for T311A, 95% for K350A, 82% for C327A, 70% for M334A, 53% for E339A, 42% for A375V, and about 3% for A375L and M334E.
## Methods
- Comparative/homology modeling was used to build mouse AhR PAS B LBD models from residues 230–421 using PSI-BLAST, structural alignment, and MODELLER; three template sets were tested, including a single-template HIF-2α model and two multitemplate models.
- Structural pockets were analyzed with CASTp, and the I332P mutant and wild-type models were examined by 1 ns molecular dynamics simulations in GROMACS.
- Site-directed mutagenesis tested selected residues (R282, H285, T311, C327, I332, M334, E339, K350, A375, Q377) in in vitro expressed mouse AhR; effects on [³H]TCDD binding and TCDD-dependent DNA binding were measured by hydroxyapatite binding assay and gel retardation assay.
## Limitations
- The paper states that the models necessarily had some stereochemical restraint violations because of the medium-low degree of similarity between mAhR and the templates; this is an explicit limitation of the modeling.
- The authors note that the ligand-binding assay is less sensitive than the gel retardation assay and that assay reagents can strip ligand from low-affinity AhRs; this is an evident experimental limitation in the text.
- The paper also says that the observed effects of some mutations, especially E339A, may reflect protein-protein interaction effects and “deserve further in-depth analyses”; this is an explicit limitation of the current study.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 6 Not checked · 66 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, deletion of residues 287-421 results in a ligand-independent constitutively active AhR consistent the role of the AhR LBD-hsp90 complex in regulating AhR functionality (18).”
What the sources say
- Partly supportedcites [18] 18. McGuire J, Okamoto K, Whitelaw ML, Tanaka H, Poellinger L. Definition of a dioxin receptor mutant that is a constitutive activator of transcription: delineation of overlapping repression and ligand binding functions within the PAS domain. J. Biol. Chem 2001;276:41841-41849. [PubMed: 11551926] sourceExperimental — accuracy not yet measured
The Abstract reports that deleting amino acids 288–421 produced a constitutively active dioxin (AhR) receptor that stimulated transcription without ligand. The cited claim gives the deletion as 287–421; our copy supports the functional result but not that exact residue range. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, deletion of residues 287-421 results in a ligand-independent constitutively active AhR consistent the role of the AhR LBD-hsp90 complex in regulating AhR functionality (18).”
What the sources say
- Supportedcites [18] 18. McGuire J, Okamoto K, Whitelaw ML, Tanaka H, Poellinger L. Definition of a dioxin receptor mutant that is a constitutive activator of transcription: delineation of overlapping repression and ligand binding functions within the PAS domain. J. Biol. Chem 2001;276:41841-41849. [PubMed: 11551926] source
The Results identify a PAS B deletion spanning amino acids 288–421 and report ligand-independent activity for that mutant. The Discussion says deleting this region produces a constitutive transcriptional activator and identifies it as a target of hsp90 regulation. The citing sentence gives the deletion boundary as 287 rather than 288, but otherwise matches the paper’s finding and interpretation. (LLM, conf=0.89)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Full ligand binding activity and specificity of the mouse AhR are reportedly contained within a small fragment (residues 230-421), and several naturally occurring mutations within this region reduce AhR ligand binding affinity (13,16,17).”
What the sources say
- Partly supportedcites [13] 13. Coumailleau P, Poellinger L, Gustafsson J-A, Whitelaw ML. Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity. J. Biol. Chem 1995;270:25291-25300. [PubMed: 7559670] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) places a naturally occurring polymorphic residue at position 375 within the 230–421 ligand-binding domain and says it influences low- versus high-affinity receptor phenotypes in mouse strains. It does not report several naturally occurring mutations in that region that reduce ligand-binding affinity. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [16] 16. Ema M, Ohe N, Suzuki M, Mimura J, Sogawa K, Ikawa S, Fujii-Kuriyama Y. Dioxin binding activities of polymorphic forms of mouse and human aryl hydrocarbon receptors. J. Biol. Chem 1994;269:27337-27343. [PubMed: 7961644] source
- Not checked — no full text of the sourcecites [17] 17. Poland A, Palen D, Glover E. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol. Pharmacol 1994;46:915-921. [PubMed: 7969080] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Homology modeling of these mutants, performed on the basis of the same template structures, alignment, and modeling procedure used for the wild-type mAhR (see Materials and Methods section), indicated that only the I332P mutation has structural effects on the LBD.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gel retardation analysis revealed that while some mutations had no significant effect on TCDDinducible DNA binding (R282A, T311A, and K350A), some mutations reduced AhR DNA binding (C327A, M334A, E339A, A375V, and Q377A) and others completely eliminated DNA binding (H285A, I332P, M334E, and A375L).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 80 claims and to verify the 4 references still open.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 11
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Given that the mutation of Q377 to alanine was proved to abolish TCDD specific binding43, this mutant could not be used to evaluate the relative affinity of BNF and IR by competitive binding analysis with [3H]TCDD.”
From Modeling the binding of diverse ligands within the Ah receptor ligand binding domain (2019) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“homology models of the AHR ligand-binding domain (LBD) are available for only a few species.”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Small variability is observed only in the loops encompassing a residue insertion (DE loop) and a two-residue deletion (HI loop) of the global alignment with the templates (17).”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When this amino acid is mutated to Val, it introduces steric hindrance at this end of the modeled cavity (Figure 2C), effectively decreasing the cavity volume and potentially affecting ligand interactions with other fingerprint residues (17,18).”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, a decrease in the internal cavity volume (below that of the consensus cavity) appears to correlate with the decreased TCDD binding affinity observed with AHRs containing other amino acids at position 375 (17,63).”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [17]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977) · Journal of Computational Physics · doi:10.1016/0021-9991(77)90098-5 · Cited by 21,239
LINCS: A linear constraint solver for molecular simulations
Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (1997) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(199709)18:12<1463::aid-jcc4>3.0.co;2-h · Cited by 18,260
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins
MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., et al. (1998) · The Journal of Physical Chemistry B · doi:10.1021/jp973084f · Cited by 14,311
Research works printed but not linked: 35
- Ma Q., 2001, Curr. Drug Metab. 2, 149−164.
- Denison M. S., 1998, Molecular Biology Approaches to Toxicology
- Denison M. S., 1998, Bull. Environ. Contam. Toxicol. 61, 557−568.
- Denison M. S., 2002, Chem.-Biol. Interact. 141, 3−24.
- Petrulis J. R., 2002, Chem.-Biol. Interact. 141, 25−40.
- Henry E. C., 2003, Mol. Pharmacol. 63, 392−400.
- Hord N. G., 1994, Mol. Pharmacol. 46, 618−624.
- Whitlock J. P., Jr., 1999, Annu. Rev. Pharmacol. Toxicol., 39
- Fukunaga B. N., 1995, J. Biol. Chem., 270
- Perdew G. H., 1996, Biochem. Mol. Biol. Int. 39, 589−593.
- Ema M., 1994, J. Biol. Chem., 269
- Poland A., 1994, Mol. Pharmacol. 46, 915−921.
- McGuire J., 2001, J. Biol. Chem., 276
- Gong W., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
- Crosson S., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
- Bonati L., 2002, Organohalogen Compd. 59, 429−432.
- Erbel P. J., 2003, Proc. Natl. Acad. Sci. U.S.A. 100
- Card P. B., 2005, J. Mol. Biol., 353
- Berman H. M., 2000, Nucleic Acids Res. 28, 235−242.
- Kelley L. A., 1996, Protein Eng. 9, 1063−1065.
- Getzoff E. D., 2003, Nat. Struct. Biol. 10, 663−668.
- Altschul S. F., 1997, Nucleic Acids Res. 25, 3389−3402.
- Fiser A., 2000, Protein Sci. 9, 1753−1773.
- MacKerell A. D., Jr., 1998, J. Phys. Chem. B, 102
- Thompson J. D., 1994, Nucleic Acids Res. 22, 4673−4680.
- Sippl M. J., 1993, Proteins 17, 355−362.
- Sanchez R., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
- Dundas J., 2006, Nucleic Acids Res. 34, W116−W118.
- Berendsen H. J. C., 1995, Comput. Phys. Commun., 91, 56
- Rushing S. R., 2002, Arch. Biochem. Biophys. 403, 189−201.
- Sali A., 1995, Proteins 23, 318−326.
- Liang J., 1998, Protein Sci. 7
- Harper P. A., 1992, Mol. Pharmacol. 42, 603−612.
- Bonati L., 1995, Part 2, J. Mol. Struct. (Theochem), 340, 95
- Meyer E. A., 2003, 42, 1210−1250.
Cited by
Items 101–160 of 160
Doering, J. A., Hecker, M., Villeneuve, D. L., & Zhang, X. (2019) · OECD series on adverse outcome pathways · doi:10.1787/bd46b538-en · Cited by 11
Gao, C., Zhang, A., Lin, Y., Yin, D., & Wang, L. (2009) · 中国科学通报:英文版 · doi:10.1007/s11434-009-0174-7 · Cited by 8
Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy
Santini, G., Bonati, L., & Motta, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-03626-z · Cited by 8
Self-citationZheng, Y., Xie, J., Huang, X., Dong, J., Park, M. S., & Chan, W. K. (2016) · Protein Expression and Purification · doi:10.1016/j.pep.2016.02.011 · Cited by 6
“One of the most notable examples is that a conserved change of alanine to valine at the ligand binding domain of the mouse AHRb allele (amino acid 375) drastically suppresses ligand binding ability [11, 12].”
BackgroundIn silico predictive studies of mAHR congener binding using homology modelling and molecular docking
Panda, R., Cleave, A. S. S., & Suresh, P. (2012) · Toxicology and Industrial Health · doi:10.1177/0748233712463774 · Cited by 7
“The key amino acids, Ile319, Cys327, His285, Ile332, Met334, Ala375 and Gln377, recognised to play a role in ligand binding in the mAHR, (Andreasen et al., 2002; Minsavage et al., 2003; Pandini et al., 2007) are well conserved across several vertebrate species (Bisson et al., 2009).”
BackgroundMosa, F. E. S., Alqahtani, M. A., El‐Ghiaty, M. A., El-Mahrouk, S. R., Barakat, K., & El‐Kadi, A. O. S. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110088 · Cited by 5
Rosales‐Hernández, M. C., Bello, M., Toledano, J. V., Feregrino, B. C. E., Correa‐Basurto, J., Morales, L. G. F., & Torres-Ramos, M. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2171132 · Cited by 7
“This result shows that, depending on the conformation of AhR, the AhR-HSP90 interaction can be activated by a ligand (Pandini et al., 2007).”
BackgroundMosa, F. E. S., El‐Kadi, A. O. S., & Barakat, K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99228 · Cited by 8
POTENCY AND SPECIES SPECIFICITY OF ARYL HYDROCARBON RECEPTOR LIGANDS
Wall, R. J. (2012) · Nottingham ePrints (University of Nottingham) · Cited by 7
Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer
Vlaar, J. M., Borgman, A., Kalkhoven, E., Westland, D., Besselink, N. J. M., Shale, C., Faltas, B. M., Priestley, P., Kuijk, E., & Cuppen, E. P. J. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-14256-0 · Cited by 6
The modern human aryl hydrocarbon receptor is more active when ancestralized by genome editing
Helmbrecht, N., Lackner, M., Maričić, T., & Pääbo, S. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402159121 · Cited by 6
“Position 381 falls within the ligand binding pocket (9) and several studies have attributed differences between mouse and human AHR ligand binding to the valine - alanine difference at position 381 (10–12).”
BackgroundPharmacological interactions between phenylbenzothiazoles and aryl hydrocarbon receptor (AhR)
Bazzi, R. (2008) · Nottingham ePrints (University of Nottingham) · Cited by 4
Farhat, A., & Kennedy, S. W. (2019) · OECD series on adverse outcome pathways · doi:10.1787/063e1bf4-en · Cited by 13
Sahoo, M. P., Samanta, L., & Satpathy, R. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00221-z · Cited by 3
“Future research on elucidation of the structure and function of AhR can be continued further by subsequent implementation and extension of the application of computational molecular modeling techniques [6, 35, 52, 60, 67, 90].”
Orlowska, K., Molcan, T., Świgońska, S., Sadowska, A., Jabłońska, M., Nynca, A., Jastrzebski, J., & Ciereszko, R. E. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.05.012 · Cited by 2
Zhang, R., Zhai, J., Wu, Q., Wei, C., Zhu, H., Shan, Q., Zhang, J., Xie, Y., Zhang, X., Peng, Y., et al. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c13745 · Cited by 2
Karabogdan, I., Yanqui-Rivera, F., Sayeeram, D., Sadik, A., Miller, A. K., Trump, S., Röhrig, U. F., & Opitz, C. A. (2026) · ACS Omega · doi:10.1021/acsomega.5c10598 · Cited by 1
Panda, R., Cleave, S. S. A., & Suresh, P. K. (2013) · International Journal of Pharma and Bio Sciences · Cited by 1
Chaves, J. D. O., de Oliveira, K. M., Figueiredo, L. S., Aguiar, G. D. S., Freitas, I. N., de Oliveira, C. D. A. R., Rios, V. K., Ribeiro, R. A., & Blanc, H. N. H. (2021) · doi:10.22533/at.ed.5472101043 · Cited by 2
Nishino, K., Someya, K., Tsukano, C., Ishikawa, T., & Nagao, M. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.100912 · Cited by 1
Expression of the Caenorhabditis elegans aryl hydrocarbon receptor ligand binding domain
Helaly, A. (2011) · UPT. Syiah Kuala University Library (Syiah Kuala University) · Cited by 1
Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancerPreprint
Vlaar, J. M., Borgman, A., Kalkhoven, E., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1486740/v1 · Cited by 1
Ligand Features Essential for Cytochrome P450 Induction
Schuster, D., Steindl, T. M., & Langer, T. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621460.ch14
Dynamic Regulation of Aryl Hydrocarbon Receptor Function and Activity by Different Stimuli
Luecke-Johansson, S. (2010) · Figshare
Recombinant Expression of Functional Mouse AhR LBD in E. coli
Elhawari, W., Bell, D., & Amer, A. H. (2019) · Nottingham ePrints (University of Nottingham) · doi:10.13140/rg.2.2.15532.08327
Fragment MO Calculations on Specific Interactions between AhR and TCDD for Beluga and Tern
Miyagi, S., Yoshikawa, E., Dedachi, K., Itoh, S., Ishihara‐Sugano, M., & Kurita, N. (2009) · Journal of Computer Aided Chemistry · doi:10.2751/jcac.10.63
Papoutsis, A. J. (2012) · UA Campus Repository (The University of Arizona)
IMOBILIZAÇÃO DE LEVEDURAS EM GEL DE ALGINATO E PECTINA
Gonçalves, L. D. F., & Rodrigues, S. Á. (2021) · doi:10.22533/at.ed.54721010411
Tulloch, H. (1982) · Pleadings, oral arguments, documents · doi:10.18356/9789211549867c008
MONITORAMENTO MICROCONTROLADO DO CULTIVO MIXOTRÓFICO DE HAEMATOCOCCUS PLUVIALIS
Pinto, L., & Anschau, A. (2021) · doi:10.22533/at.ed.54721010418
ATIVIDADES BIOLÓGICAS DE PSEUDOBOMBAX MARGINATUM (A.ST.-HIL., JUSS. & CAMBESS.) A. ROBYNS
dos Santos, N. A. M., da Silva, J. F., de Souza, T. P., & Ramalho, H. M. M. (2021) · doi:10.22533/at.ed.5472101048 · Cited by 1
A RELEVÂNCIA E OS MECANISMOS DE AÇÃO DA TOXINA BOTULÍNICA COMO TERAPÊUTICA ESTÉTICA
de Aguiar, L. M. N. M., da Silva, L. D. F. L., da Silva, S. S., dos Santos, G. M., da Silva, D. M., de Carvalho, A. M., de Matos, R. R. C., Monteiro, J. F. B., & de Aguiar, J. D. J. C. (2021) · doi:10.22533/at.ed.54721010415
Rodrigues, D. C., Walcher, D. L., da Cunha, C. N. D. O., Mattos, G. T., de Souza, N. F. G. C., de Ávila, L. F. D. C., Ramos, D. F., & Scaini, C. J. (2021) · doi:10.22533/at.ed.5472101042
EXPRESSÃO DA PROTEÍNA HIF-1α EM CARCINOMA DE CÉLULAS ESCAMOSAS DA CAVIDADE ORAL
Vimercati, B. D. S., Evaristo, S. D. O., Queiroz, M. E. S., de Oliveira, M. M., de Assis, A. L. E. M., Borçoi, A. R., de Souza, R. P., Archanjo, A. B., & da Silva, A. M. Á. (2021) · doi:10.22533/at.ed.5472101049
Francischini, I. A. G., & da Silva, C. H. T. D. P. (2021) · doi:10.22533/at.ed.54721010410
AVALIAÇÃO DE AMILASES POR FERMENTAÇÃO SUBMERSA DO FUNGO ASPERGILLUS ACULEATUS
de Vasconcelos, A. F., Chamy, M. N. C. L., Costa, A. B., Costa, B. K. B. D. S., Lima, U. D. O., Prá, A. C. D., Reis, R. D. S., & de Brito, R. G. (2021) · doi:10.22533/at.ed.5472101041
COMPOSIÇÃO QUÍMICA E ATIVIDADE ANTIBACTERIANA DO ÓLEO ESSENCIAL DE VITEX AGNUS-CASTUS L. (LAMIACEAE)
Gonçalves, R., Ayres, V. F. D. S., de Carvalho, C. E., de Souza, M. G. M., Guimarães, A. C., Corrêa, G. M., Martins, C. H. G., Takeara, R., Silva, E. D. O., & Crotti, A. E. M. (2021) · doi:10.22533/at.ed.5472101044
Leal, C. D. F., Ribeiro, L. R., & de Almeida, D. M. (2021) · doi:10.22533/at.ed.5472101047
ISOLAMENTO E IDENTIFICAÇÃO BIOQUÍMICA DE Salmonella spp. NA CADEIA PRODUTIVA DE FRANGOS
da Silva, S. E. L., Miranda, V. S., Ferreira, N. L., Tomaz, L. D., da Silva, V. S., & Silva, K. S. (2021) · doi:10.22533/at.ed.5472101045
PRODUÇÃO E APLICAÇÃO DE SOFOROLIPÍDIOS EM COSMÉTICOS
Filipe, G. A., Lonni, A. A. S. G., & Celligoi, M. A. P. C. (2021) · doi:10.22533/at.ed.54721010414 · Cited by 2
UTILIZAÇÃO DE VETORES VIRAIS NA TERAPIA GÊNICA
Barroso, E. P., Félix, S. S. L., Félix, A. J. L., Félix, M. J. E. L., Sinhorin, G. H., Júnior, Y. F. D. M., da Silva, A. G., Ferreira, J. P., de Arruda, É. F., & Filho, A. N. D. S. G. (2021) · doi:10.22533/at.ed.54721010416
EXPANSION OF SCHISTOSOMIASIS IN A LOCALITY IN SÃO LUÍS, MARANHÃO, BRAZIL
Nogueira, A. D. J. L., Mendes, R. J. D. A., Filho, A. A. P., Aguiar, L. S., Nogueira, I. B. D. C., Fabri, A. N., Ambrósio, H. T. M. D. J., Araújo, K. R. F., & Rosa, I. G. (2021) · doi:10.22533/at.ed.54721010417
CONTRACEPTIVOS ORAIS COMBINADOS E A BIOLOGIA DA INSULINA
Chaves, J. D. O., de Oliveira, C. D. A. R., Blanc, H. N. H., & Ribeiro, R. A. (2021) · doi:10.22533/at.ed.54721010412
Uma visão estrutural sobre componentes do processo de adaptação metabólica de tumores
Ambrosio, A. L. B. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2018.tde-25022021-104637 · Cited by 1
Structural variation in genomes and its role in disease
Vlaar, J. M. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/902
Lensu, S. (2014) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)
尹, 大., 高, 常., 王, 连., 张, 爱., & 蔺, 远. (2009) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb2009-54-2-161
PAS Proteins: Comparative Biology and Proteasomal Degradation
Pollenz, R. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64973-5
PAS Proteins: Comparative Biology and Proteasomal Degradation
Pollenz, R. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.20004-1
PAS Proteins: Comparative Biology and Proteasomal Degradation
Pollenz, R. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00208-6
Regulation of Cyclooxygenase-2 by Environmental and Dietary Factors
Degner, S. C. (2007) · UA Campus Repository (The University of Arizona)
Vuckovski, A., & Ackova, D. G. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6010015
Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
Gautron, A. (2019) · theses.fr (ABES) · doi:10.70675/b9c75939z7407z49abzafcbze6e92703d459
Zhu, W., Chen, Y., Hong, X., Chen, Y., Chen, W., Ouyang, Z., Gui, S., & Fan, R. (2026) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-026-00309-8
“Van der Waals and hydrophobic interactions dominate AhR–PAHs binding energy, which is consistent with the result of previous research 43 .”
Omidi, M., Shadboorestan, A., & Mohammadi‐Bardbori, A. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104779
Metadata
- Authors
- Pandini, A., Denison, M. S., Song, Y., Soshilov, A. A., & Bonati, L.
- Affiliations
- University of Milano-Bicocca (IT)
- Corresponding author
- Bonati, Laura
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-12-23
- Volume
- 46
- Issue
- 3
- Pages
- 696-708
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2860805
- OpenAlex
- W2081410156
- Semantic Scholar
- 35051ec00e96ca75b3528a869d2eb2ab08935b72
- Cited by
- 160
- References
- 68
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 9 · 2021: 24 · 2020: 10 · 2019: 11 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 10
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Brunel University Research Archive (BURA) (Brunel University London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- National Institutes of Health (5p30es005707-15)
- Division of Agriculture and Natural Resources, University of California
- National Institute of Environmental Health Sciences (F32ES005707, ES 07685, R01ES007685, ES05707, P30-ES0-05707)
- Topics
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Toxic Organic Pollutants Impact
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- aryl hydrocarbon receptor, PAS-B domain, ligand-binding domain, TCDD, homology modeling, HIF-2α, ARNT, point mutations, ligand-binding cavity, DNA binding, transcription factor activation
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Amino Acid Sequence, Animals, Binding Sites, Humans, Ligands, Models, Molecular, Molecular Sequence Data, Transcription Factors, Mutagenesis, Site-Directed, Sequence Alignment, Protein Structure, Tertiary, Receptors, Aryl Hydrocarbon, Structural Homology, Protein, Mice, Aryl Hydrocarbon Receptor Nuclear Translocator, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






